Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients
Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients
复制标题
DOI：
10.1046/j.1365-2141.2002.03654.x
复制
发表时间：
2002-09-01
影响因子：
6.5
通讯作者：
Viale, G
中科院分区：
文献类型：
--
作者：
Pruneri, G;Ponzoni, M;Viale, G
我们评估了多发性骨髓瘤（MM）患者骨髓活检（BM）中抗CD34和抗CD105抗体（mAb）染色后的微血管密度（MVD）。在对照和MM样本中，抗CD105 mAb在血管可视化方面比抗CD34 mAb显著更敏感。使用抗CD34和抗CD105 mAb时，MM中的MVD显著高于对照组。低CD34（+）MVD组生存期长于高MVD组（P = 0.01），而低CD105（+）MVD组与高CD105（+）MVD组生存期无差异。多因素分析证实CD34（+）MVD与生存率之间存在独立的显著相关性（P = 0.001）。
We evaluated microvessel density (MVD) in bone marrow biopsies (BM) from multiple myeloma (MM) patients after staining with anti-CD34 and anti-CD105 antibodies (mAbs). The anti-CD105 mAb was significantly more sensitive than the anti-CD34 mAb in visualizing blood vessels both in controls and MM samples. MVD was significantly higher in MM than in controls with both anti-CD34 and anti-CD105 mAbs. Patients with low CD34(+) MVD survived longer than patients with higher MVD (P = 0.01), whereas there was no difference in survival between patients with low and high CD105(+) MVD. Multivariate analysis confirmed the independent significant association between CD34(+) MVD and survival (P = 0.001).